155 related articles for article (PubMed ID: 37682504)
1. Impact of Cardiovascular Comorbidities on the Effectiveness and Safety of Bevacizumab in Older Patients with Metastatic Colorectal Cancer.
Gouverneur A; Favary C; Jové J; Rouyer M; Bignon E; Salvo F; Tchalla A; Paillaud E; Aparicio T; Noize P
Target Oncol; 2023 Sep; 18(5):717-726. PubMed ID: 37682504
[TBL] [Abstract][Full Text] [Related]
2. Risk of arterial and venous thromboembolic events among patients with colorectal carcinoma: a real-world, population-based study.
Abdel-Rahman O; Wu C; Easaw J
Future Oncol; 2021 Oct; 17(30):3977-3986. PubMed ID: 34342490
[TBL] [Abstract][Full Text] [Related]
3. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab.
Scappaticci FA; Skillings JR; Holden SN; Gerber HP; Miller K; Kabbinavar F; Bergsland E; Ngai J; Holmgren E; Wang J; Hurwitz H
J Natl Cancer Inst; 2007 Aug; 99(16):1232-9. PubMed ID: 17686822
[TBL] [Abstract][Full Text] [Related]
4. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study.
Kozloff MF; Berlin J; Flynn PJ; Kabbinavar F; Ashby M; Dong W; Sing AP; Grothey A
Oncology; 2010; 78(5-6):329-39. PubMed ID: 20733336
[TBL] [Abstract][Full Text] [Related]
6. Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer.
Shankaran V; Mummy D; Koepl L; Bansal A; Mirick DK; Yu E; Morlock R; Ogale S; Ramsey SD
Oncologist; 2014 Aug; 19(8):892-9. PubMed ID: 25085899
[TBL] [Abstract][Full Text] [Related]
7. MODUL cohort 2: an adaptable, randomized, signal-seeking trial of fluoropyrimidine plus bevacizumab with or without atezolizumab maintenance therapy for BRAF
Tabernero J; Grothey A; Arnold D; de Gramont A; Ducreux M; O'Dwyer P; Tahiri A; Gilberg F; Irahara N; Schmoll HJ; Van Cutsem E
ESMO Open; 2022 Oct; 7(5):100559. PubMed ID: 36029653
[TBL] [Abstract][Full Text] [Related]
8. Impact of chronological age on efficacy and safety of fluoropyrimidine plus bevacizumab in older non-frail patients with metastatic colorectal cancer: a combined analysis of individual data from two phase II studies of patients aged >75 years.
Moriwaki T; Nishina T; Sakai Y; Yamamoto Y; Shimada M; Ishida H; Amagai K; Sato M; Endo S; Negoro Y; Kuramochi H; Denda T; Hatachi Y; Ikezawa K; Nakajima G; Bando Y; Tsuji A; Yamamoto Y; Morimoto M; Kobayashi K; Hyodo I
Jpn J Clin Oncol; 2022 Jul; 52(7):725-734. PubMed ID: 35470391
[TBL] [Abstract][Full Text] [Related]
9. An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group.
Tahover E; Hubert A; Temper M; Salah A; Peretz T; Hamburger T; Uziely B
Target Oncol; 2015 Mar; 10(1):55-63. PubMed ID: 24599713
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of first-line bevacizumab plus FOLFIRI in elderly patients with metastatic colorectal cancer: Results of the ETNA observational cohort.
Rouyer M; Fourrier-Réglat A; Smith D; Becouarn Y; Guimbaud R; Tubiana-Mathieu N; Robinson P; Jové J; Grelaud A; Noize P; Moore N; Ravaud A
J Geriatr Oncol; 2016 May; 7(3):187-94. PubMed ID: 27085302
[TBL] [Abstract][Full Text] [Related]
11. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): a randomised, open-label phase 3 study.
André T; Falcone A; Shparyk Y; Moiseenko F; Polo-Marques E; Csöszi T; Campos-Bragagnoli A; Liposits G; Chmielowska E; Aubel P; Martín L; Fougeray R; Amellal N; Saunders MP
Lancet Gastroenterol Hepatol; 2023 Feb; 8(2):133-144. PubMed ID: 36470291
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial.
Romera A; Peredpaya S; Shparyk Y; Bondarenko I; Mendonça Bariani G; Abdalla KC; Roca E; Franke F; Melo Cruz F; Ramesh A; Ostwal V; Shah P; Rahuman SA; Paravisini A; Huerga C; Del Campo García A; Millán S
Lancet Gastroenterol Hepatol; 2018 Dec; 3(12):845-855. PubMed ID: 30262136
[TBL] [Abstract][Full Text] [Related]
13. Clinical outcomes associated with bevacizumab-containing treatment of metastatic colorectal cancer: the BRiTE observational cohort study.
Kozloff M; Yood MU; Berlin J; Flynn PJ; Kabbinavar FF; Purdie DM; Ashby MA; Dong W; Sugrue MM; Grothey A;
Oncologist; 2009 Sep; 14(9):862-70. PubMed ID: 19726453
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry.
Slavicek L; Pavlik T; Tomasek J; Bortlicek Z; Buchler T; Melichar B; Vyzula R; Prausova J; Finek J; Majek O; Dusek L
BMC Gastroenterol; 2014 Mar; 14():53. PubMed ID: 24666582
[TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
[TBL] [Abstract][Full Text] [Related]
16. Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer.
Arrichiello G; Perrone A; Napolitano S; Martini G; De Falco V; Incoronato P; Laterza MM; Facchini G; Famiglietti V; Nacca V; Paragliola F; Napolitano R; Suarato G; Nicastro A; Martinelli E; Ciardiello D; Ciardiello F; Troiani T
Target Oncol; 2022 Nov; 17(6):635-642. PubMed ID: 36239883
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and Safety of Bevacizumab Combined With First-Line Chemotherapy in Elderly (≥75 Years) Patients With Metastatic Colorectal Cancer: A Real-World Study.
François E; Mineur L; Deplanque G; Laplaige P; Smith D; Gourgou S; Tanang A; Ionescu-Goga M; Veerabudun K; Lelarge Y; Kim S; Rollot F
Clin Colorectal Cancer; 2020 Sep; 19(3):e100-e109. PubMed ID: 32299778
[TBL] [Abstract][Full Text] [Related]
18. Integrating geriatric assessment in the first line chemotherapy treatment in older patients with metastatic colorectal cancer: Results of a prospective observational cohort study (AVAPLUS).
Decoster L; Kenis C; Naessens B; Houbier G; De Man M; Lambrecht G; Monsaert E; Moons V; Vergauwe P; Prenen H; Van Cutsem E; Wildiers H
J Geriatr Oncol; 2018 Mar; 9(2):93-101. PubMed ID: 29133190
[TBL] [Abstract][Full Text] [Related]
19. Comparative cost-effectiveness of bevacizumab-irinotecan-fluorouracil versus irinotecan-fluorouracil in first-line metastatic colorectal cancer.
Ruiz-Millo O; Albert-Mari A; Sendra-Garcia A; Jimenez-Torres NV
J Oncol Pharm Pract; 2014 Oct; 20(5):341-50. PubMed ID: 24177355
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of First-Line Bevacizumab in Metastatic Colorectal Cancer: The Observational Cohort Study GRETA.
Franchi M; Barni S; Tagliabue G; Ricci P; Mazzucco W; Tumino R; Caputo A; Corrao G;
Oncologist; 2019 Mar; 24(3):358-365. PubMed ID: 30097524
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]